BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Celgene 

4550 Towne Centre Court

San Diego  California  92121  U.S.A.
Phone: 858-558-7500 Fax: 858-552-8775


SEARCH JOBS
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.

Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), small-cell lung and prostate cancer.

As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.


 Key Statistics


Email:
Ownership: Subsidiary

Web Site: Celgene
Employees: 2,000 worldwide
Symbol: CELG
 



Industry
Biotechnology


Collaborations

Novartis Corporation  Discovery and Development of Selective estrogen receptor modulators for the treatment of osteoporosis

Novartis Corporation  Commercialization of FocalinTM for ADHD





 Company News
Celgene Corporation (CELG) Release: Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients With Psoriatic Arthritis 5/7/2013 11:22:26 AM    More...
Celgene (CELG) Release: Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients With Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes 4/26/2013 10:17:12 AM    More...
Celgene (CELG) Reports Strong Fourth Quarter and Full Year 2012 Operating and Financial Results 1/24/2013 6:17:25 AM    More...
Celgene (CELG)'s Abraxane Keeps Pancreatic Pts Alive an Extra Two Months in Trial 1/23/2013 6:49:55 AM    More...
Celgene (CELG) Release: REVLIMID® and VIDAZA® Combination Therapy Achieves Nearly 30 Percent Complete Response in Untreated Elderly Patients With Acute Myeloid Leukemia 12/11/2012 10:13:29 AM    More...
Celgene (CELG)'s Pomalidomide Helps in Myeloma After Others Fail 12/11/2012 8:17:52 AM    More...
Celgene (CELG), Sanofi (France) (SAN.PA) Executives Charged With Insider Trading 11/19/2012 12:52:43 PM    More...
Celgene (CELG)'s Abraxane Boosts Pancreatic Cancer Survival 11/12/2012 7:30:10 AM    More...
PharmAria Announces Strategic Partnership With Celgene (CELG) 10/15/2012 11:58:14 AM    More...
Celgene (CELG)'s Abraxane is Talk of Cancer Meeting 10/1/2012 8:04:36 AM    More...
12345678910...